Limitations, agreements, and source contact

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2016-06-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

true

point Of Contact

email

asuvanna@iu.edu

organization

IndianaU

phone

317-944-0920

title

Dr. Attaya Suvannasankha

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice